(−)-Epigallocatechin gallate inhibits Mos activation-mediated Xenopus oocyte maturation induced by progesterone  by Yasokawa, Masayo et al.
(3)-Epigallocatechin gallate inhibits Mos activation-mediated
Xenopus oocyte maturation induced by progesterone
Masayo Yasokawaa, Isamu Sugimotoa, Motoyo Fukumaa, Natsuko Gotoa, Naoki Kobayashia,
Hiroko Yasudaa, Kumiko Oguraa, Jun Iwashitab, Katsumi Nagatac, Yasutake Hijic,
Eikichi Hashimotoa;*
aDepartment of Pathological Biochemistry, School of Life Sciences, Yonago 683-8503, Japan
bDepartment of Biology, Faculty of Science, Kyushu University, Hakozaki 6-10-1, Fukuoka 812-8581, Japan
cFirst Department of Physiology, Faculty of Medicine, Tottori University, 86 Nishicho, Yonago 683-8503, Japan
Received 17 November 1999
Edited by Shozo Yamamoto
Abstract (3)-Epigallocatechin gallate (EGCG), one of the
constituents of green tea known to have a tumor preventing
effect, inhibited maturation of Xenopus laevis oocytes induced by
progesterone when this polyphenol was microinjected into
oocytes at a final concentration of about 1 mM. Western blot
and activity measurement analyses showed that Mos translation
and the subsequent activations of mitogen-activated protein
kinase and p90rsk, probably by protein phosphorylation, seemed
to have been inhibited by the microinjection of EGCG. These
results suggest that EGCG may have the ability to control
Xenopus oocyte maturation at least during the stage of Mos
activation.
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1. Introduction
It has been shown that tea polyphenols such as (3)-epigal-
locatechin gallate (EGCG) have tumor preventing e¡ects
caused by antioxidative and antiproliferative activity [1]. Con-
sistent with this report, EGCG has been shown to inhibit
tumor cell growth by interfering with the binding of various
growth factors to their receptors and subsequent activation of
receptor tyrosine kinases [2] or tumor promotion induced by
the 12-O-tetradecanoyl-phorbol 13-acetate-type promoter, tel-
eocidin, in a two-step carcinogenesis system using mouse skin
[3]. Direct inhibition by EGCG of teleocidin-activated protein
kinase C (PKC) or protein-tyrosine kinase activity has also
been demonstrated in puri¢ed assay systems [2,3]. Another
report also indicated that EGCG had the ability to arrest
cell cycle transfer at the G2-M stage [4]. This evidence suggests
that EGCG may have some pleiotropic e¡ects in the control
of cell proliferation.
Recently, the decreased activity or the decreased phosphor-
ylation level of the three types of mitogen-activated protein
(MAP) kinase was demonstrated using various stimulated or
transformed cells after treatment with EGCG [5^7]. A pre-
vious report from our laboratory indicated that EGCG
showed an inhibitory e¡ect on extracellular signal-regulated-
type MAP kinase activity in vitro [8]. In an attempt to clarify
the e¡ect of EGCG on MAP kinase in a cellular system, the
Xenopus laevis oocyte was selected because MAP kinase has
been shown to play a pivotal role in oocyte maturation in-
duced by progesterone [9]. It has also been established that the
protein serine/threonine kinase cascade exists as the signal
transducing mechanism initiated by this hormone [10^12].
Among the protein kinases, Mos seemed to be the ¢rst one
whose translation was initially stimulated and then activated
by progesterone [13^18]. The present results suggest that
EGCG might seriously a¡ect oocyte maturation at a point(s)
upstream from MAP kinase.
2. Materials and methods
2.1. Materials and chemicals
X. laevis females were purchased from Johoku Seibutsu Kyozai
(Shizuoka) and maintained in aquariums at 25‡C. Collagenase (type
1A), progesterone and myelin basic protein (MBP) were obtained
from Sigma. EGCG and [Q-32P]ATP were purchased from Kurita
Kogyo (Tokyo, Japan) and Amersham, respectively. Polyclonal anti-
bodies against Mos and p90rsk and agarose-conjugated p90rsk anti-
body were obtained from Santa Cruz Biotechnology. Monoclonal
antibody against phospho(threonine-202/tyrosine-204) extracellular
signal-regulated-type MAP kinase and its agarose conjugate were pur-
chased from New England Biolabs. protein kinase A (PKA) and PKC
inhibitor peptides were prepared as indicated earlier [19]. The 40S
ribosomal subunits, prepared as indicated previously [20], were a
kind gift of Dr. K. Mizuta (Hiroshima University).
2.2. Culture of oocytes and microinjection
Xenopus ovaries were isolated as indicated earlier [19] except that
modi¢ed Barth solution medium which contained 10 mM HEPES at
pH 7.5, 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.82 mM
MgSO4, 0.33 mM Ca(NO3)2 and 0.41 mM CaCl2 was employed.
After separation into small pieces, collagenase digestion was per-
formed at a concentration of 2 mg/ml in the same medium (Ca2-
free) at room temperature with gentle rotation. Isolated oocytes were
washed thoroughly with the Ca2-containing medium and those at
stage VI were selected. EGCG was injected into about 30 oocytes in
a volume of 50 nl at a ¢nal concentration of about 1 mM using a
Dramond 203-XV autoinjector pipette. For the control, distilled water
was injected into about 30 oocytes. These oocytes were cultured in the
presence of 2 Wg/ml progesterone or the same concentration of ethanol
at 20‡C. Germinal vesicle break-down (GVBD) was observed as the
appearance of a white spot on the animal pole.
2.3. Preparation of enzymes
After incubation, oocytes were homogenized in a solution (22 Wl per
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oocyte) which contained 50 mM L-glycerophosphate at pH 7.3, 7 mM
NaF, 0.3 mM EDTA, 15 mM MgCl2, 2 mM dithiothreitol using a
pellet pestle mixer (Kontes) by 10 strokes as indicated earlier [21]. The
homogenate was ultracentrifuged at 100 000Ug for 20 min at 5‡C
using a Hitachi CS-120 ultracentrifuge and the resultant supernatant
was used as an enzyme source. The solution was divided into small
portions and stored at 380‡C until use.
2.4. Immunoprecipitation and detection of protein kinase activities
To each enzyme solution (87 Wg protein) obtained above, EGTA,
phenylmethylsulfonyl £uoride and leupeptin were supplemented at
¢nal concentrations of 1 mM (for MAP kinase) or 20 mM (for
p90rsk), 1 mM and 10 Wg/ml, respectively. An aliquot of the original
agarose-conjugated antibody (15 Wl for each enzyme) was added to
the enzyme solution and this mixture was rotated overnight (for MAP
kinase) for 2 h (for p90rsk) at 4‡C. For kinase activity measurement,
the recovered agarose gel was washed twice each with the homogeniz-
ing bu¡er containing EGTA and protease inhibitors and the kinase
bu¡er (omitting substrate and ATP) indicated below. The agarose gel
was ¢nally suspended in 50 Wl of the kinase bu¡er.
Both enzyme activities were measured based on the method de-
scribed previously [21]. The reaction mixture (40 Wl) contained
25 mM MOPS at pH 7.2, 60 mM L-glycerophosphate, 30 mM
p-nitrophenyl phosphate, 15 mM EGTA, 15 mM MgCl2, 1 mM di-
thiothreitol, 0.1 mM Na3VO4, 10 WM PKA inhibitor peptide, 10 WM
PKC inhibitor peptide, substrate protein (1 mg/ml MBP or 0.5 mg/ml
40S ribosomal subunits) and the enzyme preparation as indicated. The
reactions were started with the addition of 50 WM [Q-32P]ATP (1200
cpm/pmol). Incubation was performed at 30‡C for 30 min and the
reaction was stopped by the addition of the sodium dodecyl sulfate
(SDS) sample bu¡er, which was concentrated ¢ve times. After SDS-
polyacrylamide gel electrophoresis (PAGE), the radioactive proteins
were visualized by autoradiography with intensifying screen for 1^2
days at 380‡C.
2.5. Electrophoresis and Western blotting
SDS-PAGE was performed as described by Laemmli [22] utilizing
7.5% (for p90rsk), 12.5% (for Mos and MAP kinase and for detection
of the p90rsk activity) and 15% (for detection of the MAP kinase
activity) acrylamide separating gels and 4.5% stacking gel. Proteins
on the gel were transferred to PVDF membrane using a Trans-blot
SD Semi-dry Transfer Cell (Bio-Rad) at 12 V for 40 min according to
the manual published from the company. The procedures for blocking
with 5% skim milk solution and the subsequent reactions with anti-
bodies were essentially the same as those indicated earlier [23].
2.6. Determinations
Protein was determined with bovine serum albumin as a standard
according to the method of Bradford [24]. Concentration of the 40S
ribosomal subunit was determined as described previously [25]. Ra-
dioactivity was determined with a Beckman LS-5801 liquid scintilla-
tion counter with Cerenkov radiation.
3. Results
3.1. E¡ect of microinjection of EGCG on oocyte maturation
and Mos activation
Xenopus oocytes were microinjected with EGCG or distilled
water and stimulated with progesterone. As shown in Fig. 1A,
GVBD was observed in about 80% of water-injected oocytes
at 7 h incubation with the hormone. However, only 20% of
EGCG-injected oocytes exhibited GVBD at the same time.
This result indicated that EGCG had some inhibitory e¡ect
on oocyte maturation by progesterone.
It has been well known that Mos translation is stimulated
by progesterone and this process is necessary for activation of
the MAP kinase cascade and oocyte maturation [9^11,13^18].
In the next experiment, the enzyme extracts were examined for
Mos production by an immunoblot procedure. As indicated in
Fig. 1B, Mos protein was detected in the sample prepared
from progesterone-treated oocytes in the absence of EGCG.
On the other hand, the trace of the protein band was detected
in the sample prepared from EGCG-microinjected oocytes.
3.2. E¡ect of microinjection of EGCG on oocyte MAP kinase
and p90rsk activation
Based on the previous reports, it has been established that
MAP kinase and p90rsk are protein kinases existing down-
stream from Mos [9^12,16^18,26]. In the next experiments,
the e¡ect of microinjected EGCG was examined on both ki-
nase activations using the immunoblot procedure and activity
measurement. The immunoblot analysis of MAP kinase was
examined using an antibody which can recognize activated
extracellular signal-regulated-type MAP kinase by phosphor-
ylation of both the threonine and tyrosine residues [27]. A
more dense protein band was detected using the sample pre-
pared from the hormone-treated and non-EGCG-injected oo-
cytes (Fig. 2A, above). Consistent with this result, several-fold
higher MAP kinase activity was detected using the immuno-
precipitated enzyme prepared from the same oocyte extract
compared with that from EGCG-injected oocytes (Fig. 2A,
below).
As it has been well known that p90rsk is one of the substrate
proteins of MAP kinase [12,18,26], the same set of experi-
ments were performed on this protein kinase. The results ob-
tained were quite similar to those of MAP kinase. In immu-
noblot analysis, the slower-migrated protein band, probably
due to protein phosphorylation, was observed using the en-
zyme preparation from hormone-treated and non-EGCG-in-
jected oocytes (Fig. 2B, above). In contrast, the trace of the
mobility shift of p90rsk was detected using the sample pre-
pared from EGCG-injected oocytes. Consistent with this re-
sult, the higher S6 protein kinase activity was detected using
the enzyme sample from hormone-treated and non-EGCG-
Fig. 1. Inhibition of oocyte maturation (A) and Mos production (B)
by microinjection of EGCG. About 30 oocytes each were microin-
jected with distilled water (a) and EGCG (O), respectively, and
stimulated with progesterone; at the time indicated, GVBD was ob-
served as indicated under Section 2. The percentages of oocytes
showing GVBD are presented. After incubation for 7 h, each group
of oocytes was homogenized and a crude enzyme solution was pre-
pared; an aliquot of each preparation (10 Wg of protein) was sub-
jected to Western blot analyses using Mos antibody. Lanes 1 and 2
correspond to the samples prepared from water-injected and hor-
mone-treated, and EGCG-injected and hormone-treated oocytes, re-
spectively. The arrowhead indicates the position of Mos. Numbers
on the left side show the positions of molecular mass markers in
kDa.
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injected oocytes compared with that of EGCG-injected oo-
cytes (Fig. 2B, below).
4. Discussion
The results depicted in Fig. 1A show the inhibition of
GVBD by the microinjection of EGCG at a ¢nal concentra-
tion of 1 mM. When EGCG was injected into oocytes at a
¢nal concentration of 0.5 mM, inhibition of GVBD was not
clear (data not shown). The reason why a relatively higher
concentration of EGCG was needed may be due to the nature
of this compound having the ability to bind easily to various
intracellular constituents [1,2].
At ¢rst, we initiated this experiment to examine whether
EGCG might show an inhibitory e¡ect on extracellular sig-
nal-regulated-type MAP kinase in progesterone-treated oo-
cytes as predicted from the previous analysis performed in
vitro [8]. The present results unexpectedly showed that the
primary target of EGCG might exist during the process of
Mos activation. Previous results indicated that the translation
of Mos was stimulated in progesterone-stimulated oocytes
[13,14] and this protein plays important roles in both the
initiation of oocyte maturation [9^11,13^15] and subsequent
metaphase arrest as the cytostatic factor [28,29]. For the oo-
cyte maturation, the activation of Cdc2 kinase by progester-
one is essential [10^14]. The signal transduction pathway be-
tween Mos and Cdc2 kinase has been extensively studied by
many investigators in both in vitro and cellular systems [10^
12,16^18]. At present, MAP kinase kinase, MAP kinase,
p90rsk and Myt1 have been identi¢ed as constituents of this
protein kinase cascade [9^12,16^18]. It has been shown that
Cdc2 kinase is usually inactivated by the phosphorylation on
both threonine-14 and tyrosine-15 residues by Myt1 kinase
[30]. When oocytes are stimulated by progesterone, it has
been shown that Myt1 is phosphorylated by p90rsk and thus
inactivated [12]. The signi¢cant role of Mos in activation of
this protein kinase cascade was con¢rmed using oocytes pre-
pared from Mos knock-out mice [31,32]. In our experiment,
the extent of activation of MAP kinase and p90rsk due to
protein phosphorylation was dependent on the translation of
Mos and these kinase activities were kept low when Mos
production was inhibited by EGCG. Recent evidence supports
the idea that the inactive Cdc2 kinase is activated by a protein
phosphatase Cdc25 under the decreased activity of Myt1 dur-
ing the oocyte maturation by progesterone [12,33].
Although Mos is known as a proto-oncogene product
[13,15,34], its function has not been con¢rmed yet in the bio-
logical system except for its role in the initiation of meiotic
maturation and subsequent metaphase arrest in oocytes [13^
15,28,29]. However, previous results indicate that the constit-
utive activation of MAP kinase kinase by Mos can induce
cellular transformation [35,36]. One result from our labora-
tory indicates that extracellular signal regulated-type MAP
kinase was inhibited by a relatively lower concentration of
EGCG in vitro [8]. If this action of EGCG is demonstrated
in the cellular system, this e¡ect of EGCG on MAP kinase
may relate to the tumor preventing e¡ect of green tea [1]. The
inhibitory e¡ect of EGCG on the activity or the phosphory-
lation state of three types of MAP kinase was demonstrated
using various stimulated or transformed cells [5^7]. More re-
cently, the molecular mechanisms of Mos activation have
been shown to be very complicated [37^39]. However, the
exact target of EGCG in this process remains to be explored.
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